PMID- 37716924
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231119
IS  - 2191-0855 (Print)
IS  - 2191-0855 (Electronic)
IS  - 2191-0855 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Sep 16
TI  - Effects of Bifidobacterium BL21 and Lacticaseibacillus LRa05 on gut microbiota in 
      type 2 diabetes mellitus mice.
PG  - 97
LID - 10.1186/s13568-023-01603-1 [doi]
LID - 97
AB  - Gut dysbiosis causes damage to the intestinal barrier and is associated with type 
      2 diabetes mellitus (T2DM). We tested the potential protective effects of 
      probiotic BL21 and LRa05 on gut microbiota in type 2 diabetes mellitus mice and 
      determined whether these effects were related to the modulation of gut 
      microbiota.Thirty specific pathogen-free C57BL/6J mice were randomly allocated to 
      three groups-the (CTL) control group, HFD/STZ model (T2DM) group, and 
      HFD/STZ-probiotic intervention (PRO) group-and intragastrically administered 
      strains BL21 and LRa05 for 11 weeks. The administration of strains BL21 and LRa05 
      significantly regulated blood glucose levels, accompanied by ameliorated 
      oxidative stress in mice. The BL21/LRa05-treated mice were protected from liver, 
      cecal, and colon damage. Microbiota analysis showed that the cecal and fecal 
      microbiota of the mice presented significantly different spatial distributions 
      from one another. Principal coordinate analysis results indicated that both T2DM 
      and the BL21/LRa05 intervention had significant effects on the cecal contents and 
      fecal microbiota structure. In terms of the fecal microbiota, an abundance of 
      Akkermansia and Anaeroplasma was noted in the PRO group. In terms of the cecal 
      content microbiota, enrichment of Akkermansia, Desulfovibrio, Bifidobacterium, 
      Lactobacillus, and Limosilactobacillus was noted in the PRO group. The probiotics 
      BL21 and LRa05 prevent or ameliorate T2DM by regulating the intestinal flora and 
      reducing inflammation and oxidative stress. Our results suggest that BL21 and 
      LRa05 colonize in the cecum. Thus, BL21/LRa05 combined with probiotics having a 
      strong ability to colonize in the colon may achieve better therapeutic effects in 
      T2DM. Our study illustrated the feasibility and benefits of the combined use of 
      probiotics and implied the importance of intervening at multiple intestinal sites 
      in T2DM mice.
CI  - (c) 2023. Springer-Verlag GmbH Germany, part of Springer Nature.
FAU - Gai, Zhonghui
AU  - Gai Z
AD  - Department of Research and Development, Wecare Probiotics Co., Ltd., Suzhou, 
      215200, China.
FAU - Liao, Wenyan
AU  - Liao W
AD  - State Key Laboratory of Dairy Biotechnology, Technology Center Bright Dairy & 
      Food Co., Ltd., Shanghai, 200436, China.
FAU - Huang, Yue
AU  - Huang Y
AD  - Department of Food Science, Shanghai Business School, 2271# Zhongshanxilu Road, 
      Shanghai, 200235, China.
FAU - Dong, Yao
AU  - Dong Y
AD  - Department of Research and Development, Wecare Probiotics Co., Ltd., Suzhou, 
      215200, China.
FAU - Feng, Huafeng
AU  - Feng H
AD  - Department of Food Science, Shanghai Business School, 2271# Zhongshanxilu Road, 
      Shanghai, 200235, China.
FAU - Han, Mei
AU  - Han M
AUID- ORCID: 0000-0001-6155-3205
AD  - Department of Food Science, Shanghai Business School, 2271# Zhongshanxilu Road, 
      Shanghai, 200235, China. hanmei.918521@163.com.
LA  - eng
GR  - 32102007/National Natural Science Foundation of China/
GR  - 19DZ2281400/Shanghai Engineering Center of Dairy Biotechnology/
GR  - 2019YFC1605800/National Key Research and Development Project of China/
PT  - Journal Article
DEP - 20230916
PL  - Germany
TA  - AMB Express
JT  - AMB Express
JID - 101561785
PMC - PMC10505128
OTO - NOTNLM
OT  - Gut microbiota
OT  - Inflammation
OT  - Probiotics
OT  - Spatial structure
OT  - T2DM
COIS- All authors declare that they have no competing interests in the subject matter 
      or materials discussed in this manuscript.
EDAT- 2023/09/17 00:41
MHDA- 2023/09/17 00:42
PMCR- 2023/09/16
CRDT- 2023/09/16 23:03
PHST- 2023/06/07 00:00 [received]
PHST- 2023/09/01 00:00 [accepted]
PHST- 2023/09/17 00:42 [medline]
PHST- 2023/09/17 00:41 [pubmed]
PHST- 2023/09/16 23:03 [entrez]
PHST- 2023/09/16 00:00 [pmc-release]
AID - 10.1186/s13568-023-01603-1 [pii]
AID - 1603 [pii]
AID - 10.1186/s13568-023-01603-1 [doi]
PST - epublish
SO  - AMB Express. 2023 Sep 16;13(1):97. doi: 10.1186/s13568-023-01603-1.